Kidney Disease, Leadership Review



Roche Holding AG

Roche Holding AG announced resignation of Franz Humer as chief executive. Humer, 61, led Roche's drive to develop a leading line of cancer drugs. As he handed over his duties to Severin Schwan, formerly head of Roche's diagnostics unit, the company has the richest valuation of any large European pharmaceutical business and the most promising portfolio of new drugs.
 

La Jolla Pharmaceutical Co.

La Jolla Pharmaceutical Co. confirmed promotion of Luke Seikkula to the position of Vice President, Manufacturing, reporting to Deirdre Gillespie, President & CEO. The effective date of this promotion was February 5, 2007.
 

Nxstage Medical Inc.

Nxstage Medical Inc. announced that Emil Paganini, MD, formerly Section Head of Dialysis and Extracorporeal Therapy with the Cleveland Clinic Foundation, has joined the company as Critical Care Medical Advisor. Dr.

Keryx Biopharmaceuticals Inc.

Keryx Biopharmaceuticals Inc. announced that as a result of cost-cutting initiatives resulting from the recent clinical failure of Sulonex, the company's Chief Accounting Officer, Mark Stier will resign effective June 30, 2008.
 

Ambrx Inc

Ambrx Inc. announced the appointment of Douglas W. Axelrod, M.D., Ph.D., as Senior Vice President for Clinical Research and Development. Axelrod joins Ambrx after a productive career spanning nearly two decades at Procter & Gamble Pharmaceuticals.

Synvista Therapeutics, Inc

On March 25, 2008, the Audit Committee of the Board of Directors of Synvista Therapeutics, Inc. named Wendy A. Milici, age 36, as the Company's principal financial officer. Ms.

DaVita

DaVita’s chief medical officer Charles McAllister, MD, retired April 1, according to the dialysis provider. McAllister became DaVita’s CMO in 2000 and stepped down in July 2007. He has since served as CMO emeritus in the Office of the CMO. More.
 

Takeda Pharmaceuticals North America Inc

Takeda Pharmaceuticals North America Inc. announced proposed new leadership for Takeda America Holdings Inc. (TAH), Takeda Pharmaceuticals North America Inc. (TPNA) and Takeda Global Research & Development Center Inc. (TGRD) following an earlier announcement related to Takeda's plans to conclude its joint venture in the United States, TAP Pharmaceutical Products Inc. (TAP).

Nxstage Medical Inc.

Nxstage Medical Inc. announced that Tom Shea has joined the Company as Senior Vice President of Manufacturing Operations, effective March 31, 2008. Mr. Shea will be responsible for all of NxStage's manufacturing operations, including the Company's five manufacturing facilities. Mr. Shea joins NxStage with more than 20 years of operational management experience. Prior to joining NxStage, Mr.

Keryx Biopharmaceuticals Inc.

Keryx Biopharmaceuticals Inc. announced that, on March 26, 2008, the Company notified its President, I. Craig Henderson, M.D., that it is terminating his employment with the Company, effective as of April 15, 2008. Dr. Henderson will remain in his position as a Director of the Company until the Company's next annual meeting.
 
Syndicate content